FDA issued a warning against the use of ovarian cancer screening tests such as the CA 125 test. The agency said that erroneous results may lead women to either forgo treatment or undergo unnecessary care.
FDA issued a warning against the use of ovarian cancer screening tests such as the CA 125 test. The agency said that erroneous results may lead women to either forgo treatment or undergo unnecessary care.
Share this Article
Recommended